Core Viewpoint - YS Biopharma has appointed Ms. Rui Yu as the new Chairperson of its Audit Committee, effective January 7, 2024, enhancing its governance structure and expertise in the biopharmaceutical sector [1]. Group 1: Board Committee Membership - The Audit Committee will now consist of Rui Yu (Chairperson), Viren Mehta, and Shaojing Tong [2]. - The Compensation Committee will include Viren Mehta (Chairperson), Ajit Shetty, Shaojing Tong, and Rui Yu [2]. - The Nominating and Corporate Governance Committee will be chaired by Ajit Shetty, with members Viren Mehta, Rui Yu, and Yi Zhang [2]. Group 2: Company Overview - YS Biopharma is focused on discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer [2]. - The company has developed a proprietary PIKA® immunomodulating technology platform aimed at improving vaccines for Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles [2]. - YS Biopharma operates in multiple countries, including China, the United States, Singapore, and the Philippines, and is led by a management team with extensive experience in the biopharmaceutical industry [2].
YS Biopharma Announces Changes to its Board Committees